Encorafenib
Information
- Drug Name
- Encorafenib
- Description
- Entry(CIViC)
- 3
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| colorectal cancer | BRAF V600 BRAF V600 | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 28363909 | Detail |
| colorectal cancer | BRAF V600 BRAF V600 | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 28363909 | Detail |
| melanoma | BRAF V600 BRAF V600 | A |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 5 | 29573941 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In a Phase Ib Dose-Escalation Study of Encorafenib... | BRAF | BRAF V600 BRAF V600 | Sensitivity | true | CIViC Evidence | detail |
| In a Phase Ib Dose-Escalation Study of Encorafenib... | BRAF | BRAF V600 BRAF V600 | Sensitivity | true | CIViC Evidence | detail |
| In a phase 3 trial, patients with melanoma with BR... | BRAF | BRAF V600 BRAF V600 | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04221438 | Active, not recruiting | Phase 2 | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | September 22, 2021 | February 28, 2025 |
| NCT05004350 | Active, not recruiting | Phase 2 | A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | September 14, 2021 | January 11, 2025 |
| NCT04585815 | Active, not recruiting | Phase 1/Phase 2 | Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | November 10, 2020 | June 17, 2024 |
| NCT04657991 | Active, not recruiting | Phase 3 | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | January 15, 2021 | June 30, 2026 |
| NCT03839342 | Active, not recruiting | Phase 2 | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations | June 7, 2019 | December 2024 |
| NCT04800822 | Active, not recruiting | Phase 1 | PF-07284892 in Participants With Advanced Solid Tumors | March 17, 2021 | November 29, 2025 |
| NCT03864042 | Active, not recruiting | Phase 1 | Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | January 2, 2018 | June 30, 2023 |
| NCT03898908 | Active, not recruiting | Phase 2 | Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain | July 18, 2019 | October 10, 2023 |
| NCT03915951 | Active, not recruiting | Phase 2 | An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | June 4, 2019 | October 1, 2024 |
| NCT05195632 | Active, not recruiting | Phase 2 | Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer | June 2, 2022 | May 2025 |
| NCT02910700 | Active, not recruiting | Phase 2 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | December 9, 2016 | December 8, 2024 |
| NCT05039177 | Active, not recruiting | Phase 1/Phase 2 | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies | September 20, 2021 | December 2024 |
| NCT05260684 | Completed | Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US | January 17, 2022 | December 31, 2023 | |
| NCT03843775 | Completed | Phase 1/Phase 2 | A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | February 14, 2019 | September 2, 2023 |
| NCT02834364 | Completed | Phase 2 | BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) | June 2016 | March 29, 2023 |
| NCT02857270 | Completed | Phase 1 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | September 29, 2016 | October 24, 2022 |
| NCT05003622 | Completed | Phase 1 | Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors | September 27, 2021 | May 6, 2022 |
| NCT02902042 | Completed | Phase 1/Phase 2 | Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | April 24, 2018 | November 30, 2020 |
| NCT03693170 | Completed | Phase 2 | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | January 17, 2019 | April 27, 2023 |
| NCT02928224 | Completed | Phase 3 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | October 13, 2016 | November 10, 2022 |
| NCT06411600 | Not yet recruiting | Phase 2 | Combination Therapy for BRAF-V600E Metastatic CRCm | May 1, 2024 | May 1, 2029 |
| NCT05304546 | Not yet recruiting | Phase 2 | Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | June 2023 | June 2027 |
| NCT04061980 | Recruiting | Phase 2 | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | October 30, 2020 | October 30, 2026 |
| NCT03543969 | Recruiting | Early Phase 1 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | June 14, 2018 | July 2028 |
| NCT03563729 | Recruiting | Phase 2 | Melanoma Metastasized to the Brain and Steroids | June 6, 2018 | June 6, 2028 |
| NCT04017650 | Recruiting | Phase 1/Phase 2 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | June 14, 2019 | June 30, 2025 |
| NCT04045691 | Recruiting | Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment | October 17, 2019 | September 2027 | |
| NCT04324112 | Recruiting | Phase 2 | Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | October 28, 2020 | July 31, 2028 |
| NCT04511013 | Recruiting | Phase 2 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | January 6, 2021 | June 30, 2027 |
| NCT04607421 | Recruiting | Phase 3 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | December 21, 2020 | November 15, 2026 |
| NCT04673955 | Recruiting | BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment | September 3, 2020 | January 2027 | |
| NCT04720768 | Recruiting | Phase 1/Phase 2 | Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE | June 4, 2020 | December 4, 2024 |
| NCT05615818 | Recruiting | Phase 3 | Personalized Medicine for Advanced Biliary Cancer Patients | May 29, 2024 | June 2028 |
| NCT05710406 | Recruiting | Phase 2/Phase 3 | Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer | May 30, 2023 | August 2034 |
| NCT05725200 | Recruiting | Phase 2 | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | September 27, 2022 | December 31, 2040 |
| NCT05743036 | Recruiting | Phase 1/Phase 2 | ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | February 27, 2023 | September 25, 2026 |
| NCT05926960 | Recruiting | Phase 2 | A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma | June 13, 2023 | May 23, 2027 |
| NCT05985954 | Recruiting | Phase 1 | Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | January 18, 2024 | March 28, 2028 |
| NCT06102902 | Recruiting | Phase 1 | Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer | June 5, 2024 | June 30, 2025 |
| NCT06194929 | Recruiting | Phase 1/Phase 2 | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | February 8, 2024 | January 15, 2030 |
| NCT05026983 | Recruiting | Phase 2 | Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | December 27, 2021 | May 1, 2025 |
| NCT05217446 | Recruiting | Phase 2 | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer | July 11, 2022 | March 28, 2027 |
| NCT05308446 | Recruiting | Phase 2 | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | July 19, 2022 | August 31, 2024 |
| NCT05538130 | Recruiting | Phase 1 | A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors | November 30, 2022 | September 28, 2028 |
| NCT04801966 | Terminated | N/A | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | September 23, 2021 | December 30, 2022 |
| NCT04655157 | Terminated | Phase 1/Phase 2 | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma | May 28, 2021 | September 20, 2022 |
| NCT04390243 | Terminated | Phase 2 | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation | November 16, 2020 | November 1, 2023 |
| NCT03911869 | Terminated | Phase 2 | An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis | April 30, 2019 | January 27, 2022 |
| NCT03973918 | Terminated | Phase 2 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG | July 29, 2019 | October 1, 2023 |
| NCT04044430 | Terminated | Phase 1 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | August 31, 2020 | July 31, 2022 |
| NCT03878719 | Terminated | Phase 1 | Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma | August 3, 2020 | August 19, 2022 |
| NCT02675946 | Unknown status | Phase 1 | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | February 2016 | March 2023 |
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- LGX818
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- LGX818
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Raf
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Raf